These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Bermas BL Curr Opin Rheumatol; 2014 May; 26(3):334-40. PubMed ID: 24663106 [TBL] [Abstract][Full Text] [Related]
28. One year in review 2018: novelties in the treatment of rheumatoid arthritis. Bortoluzzi A; Furini F; Generali E; Silvagni E; Luciano N; Scirè CA Clin Exp Rheumatol; 2018; 36(3):347-361. PubMed ID: 29798748 [TBL] [Abstract][Full Text] [Related]
29. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Alam J; Jantan I; Bukhari SNA Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758 [TBL] [Abstract][Full Text] [Related]
30. Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs. Takakubo Y; Oki H; Naganuma Y; Saski K; Sasaki A; Tamaki Y; Suran Y; Konta T; Takagi M Curr Rheumatol Rev; 2017; 13(1):72-78. PubMed ID: 27030253 [TBL] [Abstract][Full Text] [Related]
31. [Disease-modifying effects of glucocorticoids in rheumatoid arthritis]. Buttgereit F; Burmester G; Bijlsma JW; Z Rheumatol; 2007 Oct; 66(6):522-4. PubMed ID: 17571272 [TBL] [Abstract][Full Text] [Related]
32. Treatment of rheumatoid arthritis: Unraveling the conundrum. Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757 [TBL] [Abstract][Full Text] [Related]
33. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934 [TBL] [Abstract][Full Text] [Related]
34. Effects of DMARDs on IL-1Ra levels in rheumatoid arthritis: is there any evidence? Cutolo M Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S26-31. PubMed ID: 14989426 [TBL] [Abstract][Full Text] [Related]
35. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis. Kim G; Barner JC; Rascati K; Richards K J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001 [TBL] [Abstract][Full Text] [Related]
37. [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]. Kleinert S; Krueger K Z Rheumatol; 2011 Aug; 70(6):464-72. PubMed ID: 21863467 [TBL] [Abstract][Full Text] [Related]
38. Patterns of medication use during pregnancy in rheumatoid arthritis. Kuriya B; Hernández-Díaz S; Liu J; Bermas BL; Daniel G; Solomon DH Arthritis Care Res (Hoboken); 2011 May; 63(5):721-8. PubMed ID: 21557526 [TBL] [Abstract][Full Text] [Related]
39. Biological response modifiers in the management of rheumatoid arthritis. Louie SG; Park B; Yoon H Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216 [TBL] [Abstract][Full Text] [Related]
40. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Smith MD; Weedon H; Papangelis V; Walker J; Roberts-Thomson PJ; Ahern MJ Rheumatology (Oxford); 2010 May; 49(5):862-75. PubMed ID: 20147446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]